Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orutexer Oral Ointment (オルテクサー口腔用軟膏) is a topical corticosteroid formulation containing triamcinolone acetonide (0.1%) as its active ingredient. Developed by Bee Brand Medico Dental for prescription use and Fukuchi Pharmaceutical for over-the-counter (OTC) use, it is specifically designed to treat oral mucosal lesions. The ointment utilizes a specialized adhesive base (containing carboxyvinyl polymer) that adheres firmly to the wet oral mucosa, forming a protective gel barrier that resists being washed away by saliva. Triamcinolone acetonide exerts potent anti-inflammatory, anti-allergic, and immunosuppressive effects by binding to and activating the glucocorticoid receptor, thereby reducing pain and promoting healing. It is primarily indicated for chronic desquamative gingivitis, refractory stomatitis (canker sores/aphthous ulcers), and glossitis accompanied by erosion or ulceration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Orutexer Oral Ointment.